184 related articles for article (PubMed ID: 35732297)
1. Industry sponsorship bias in cost effectiveness analysis: registry based analysis.
Xie F; Zhou T
BMJ; 2022 Jun; 377():e069573. PubMed ID: 35732297
[TBL] [Abstract][Full Text] [Related]
2. Sponsorship bias in oncology cost effectiveness analysis.
Zhou T; Xie F
J Clin Epidemiol; 2023 Apr; 156():22-29. PubMed ID: 36773749
[TBL] [Abstract][Full Text] [Related]
3. Do Quality-Adjusted Life Years Discriminate Against the Elderly? An Empirical Analysis of Published Cost-Effectiveness Analyses.
Xie F; Zhou T; Humphries B; Neumann PJ
Value Health; 2024 Jun; 27(6):706-712. PubMed ID: 38548176
[TBL] [Abstract][Full Text] [Related]
4. Cost-Effectiveness of Treatment Options for Neuropathic Pain: a Systematic Review.
Ruiz-Negrón N; Menon J; King JB; Ma J; Bellows BK
Pharmacoeconomics; 2019 May; 37(5):669-688. PubMed ID: 30637713
[TBL] [Abstract][Full Text] [Related]
5. Are Estimates of the Health Opportunity Cost Being Used to Draw Conclusions in Published Cost-Effectiveness Analyses? A Scoping Review in Four Countries.
Vallejo-Torres L; García-Lorenzo B; Edney LC; Stadhouders N; Edoka I; Castilla-Rodríguez I; García-Pérez L; Linertová R; Valcárcel-Nazco C; Karnon J
Appl Health Econ Health Policy; 2022 May; 20(3):337-349. PubMed ID: 34964092
[TBL] [Abstract][Full Text] [Related]
6. Trends in Author-Reported Cost-Effectiveness Thresholds in the United States from 1995 to 2018: Implications for Discount Rates.
Pandya A; Paulden M; Zhu J; Lavelle TA; Hammitt J
Med Decis Making; 2022 Oct; 42(7):885-892. PubMed ID: 35531945
[TBL] [Abstract][Full Text] [Related]
7. Differences in the Selection of Health State Utility Values by Sponsorship in Published Cost-Effectiveness Analyses.
Hendrix N; Kim DD; Patel KS; Devine B
Med Decis Making; 2021 Apr; 41(3):366-372. PubMed ID: 33451278
[TBL] [Abstract][Full Text] [Related]
8. Impact of vaccine herd-protection effects in cost-effectiveness analyses of childhood vaccinations. A quantitative comparative analysis.
Holubar M; Stavroulakis MC; Maldonado Y; Ioannidis JP; Contopoulos-Ioannidis D
PLoS One; 2017; 12(3):e0172414. PubMed ID: 28249046
[TBL] [Abstract][Full Text] [Related]
9. Patient adherence: a blind spot in cost-effectiveness analyses?
Rosen AB; Spaulding AB; Greenberg D; Palmer JA; Neumann PJ
Am J Manag Care; 2009 Sep; 15(9):626-32. PubMed ID: 19747027
[TBL] [Abstract][Full Text] [Related]
10. Industry sponsorship and research outcome.
Lundh A; Sismondo S; Lexchin J; Busuioc OA; Bero L
Cochrane Database Syst Rev; 2012 Dec; 12():MR000033. PubMed ID: 23235689
[TBL] [Abstract][Full Text] [Related]
11. When are statins cost-effective in cardiovascular prevention? A systematic review of sponsorship bias and conclusions in economic evaluations of statins.
Catalá-López F; Sanfélix-Gimeno G; Ridao M; Peiró S
PLoS One; 2013; 8(7):e69462. PubMed ID: 23861972
[TBL] [Abstract][Full Text] [Related]
12. Perspective and Costing in Cost-Effectiveness Analysis, 1974-2018.
Kim DD; Silver MC; Kunst N; Cohen JT; Ollendorf DA; Neumann PJ
Pharmacoeconomics; 2020 Oct; 38(10):1135-1145. PubMed ID: 32696192
[TBL] [Abstract][Full Text] [Related]
13. Beware of Kinked Frontiers: A Systematic Review of the Choice of Comparator Strategies in Cost-Effectiveness Analyses of Human Papillomavirus Testing in Cervical Screening.
O'Mahony JF; Naber SK; Normand C; Sharp L; O'Leary JJ; de Kok IM
Value Health; 2015 Dec; 18(8):1138-51. PubMed ID: 26686801
[TBL] [Abstract][Full Text] [Related]
14. Herd Immunity Effects in Cost-Effectiveness Analyses among Low- and Middle-Income Countries.
Ma S; Lavelle TA; Ollendorf DA; Lin PJ
Appl Health Econ Health Policy; 2022 May; 20(3):395-404. PubMed ID: 35001292
[TBL] [Abstract][Full Text] [Related]
15. Do Cost-Effectiveness Analyses Account for Drug Genericization? A Literature Review and Assessment of Implications.
Neumann PJ; Podolsky MI; Basu A; Ollendorf DA; Cohen JT
Value Health; 2022 Jan; 25(1):59-68. PubMed ID: 35031100
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of HPV vaccination in 195 countries: A meta-regression analysis.
Rosettie KL; Joffe JN; Sparks GW; Aravkin A; Chen S; Compton K; Ewald SB; Mathew EB; Michael D; Pedroza Velandia P; Miller-Petrie MB; Stafford L; Zheng P; Weaver MR; Murray CJL
PLoS One; 2021; 16(12):e0260808. PubMed ID: 34928971
[TBL] [Abstract][Full Text] [Related]
17. Industry sponsorship and publication bias among animal studies evaluating the effects of statins on atherosclerosis and bone outcomes: a meta-analysis.
Anglemyer AT; Krauth D; Bero L
BMC Med Res Methodol; 2015 Mar; 15():12. PubMed ID: 25880564
[TBL] [Abstract][Full Text] [Related]
18. Sponsorship Bias in Base-Case Values and Uncertainty Bounds of Health Economic Evaluations? A Systematic Review of Herpes Zoster Vaccination.
Bilcke J; Verelst F; Beutels P
Med Decis Making; 2018 Aug; 38(6):730-745. PubMed ID: 29799803
[TBL] [Abstract][Full Text] [Related]
19. 30 years of pharmaceutical cost-utility analyses: growth, diversity and methodological improvement.
Neumann PJ; Fang CH; Cohen JT
Pharmacoeconomics; 2009; 27(10):861-72. PubMed ID: 19803540
[TBL] [Abstract][Full Text] [Related]
20. Spine device clinical trials: design and sponsorship.
Cher DJ; Capobianco RA
Spine J; 2015 May; 15(5):1133-40. PubMed ID: 25637470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
